This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
|Security||CASI / CASI Pharmaceuticals, Inc. (14757U109)|
|CEO and Director||Ren Ken|
|Industry||Biological Products, Except Diagnostic Substances (Biotech)|
|Institutional Shares||5,266,541 - 6.11%|
|Common Shares Outstanding||86,145,298 shares (as of 2018-03-31)|
|Institutional Value||$ 21,134,000 USD|
Institutional Stock Ownership and Shareholders()
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has 50 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,266,541 shares.
Largest shareholders include
Vanguard Group Inc, Wellington Shields Capital Management, LLC, Wellington Shields & Co., LLC, Millennium Management Llc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Geode Capital Management, Llc, Goldman Sachs Group Inc, Susquehanna International Group, Llp, and California Public Employees Retirement System.
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/casi"><img src="https://images.fintel.io/us-casi-so.png" alt="CASI / CASI Pharmaceuticals, Inc. Institutional Ownership"><a>
|Virtu Financial LLC||12,124||0||-100.00||39||0||-100.00|
|DEUTSCHE BANK AG\||1,721||21||-98.78||5||0||-100.00|
|IFP Advisors, Inc||2||2||0.00||0||0|
|Advisor Group, Inc.||90||90||0.00||0||0|
|Moors & Cabot, Inc.||24,663||22,935||-7.01||82||96||17.07|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||24,541||140,680||473.24||80||587||633.75|
|BlackRock Institutional Trust Company, N.A.||225,650||225,650||0.00||250||259||3.60|
|VANGUARD GROUP INC||936,186||1,285,475||37.31||3,042||5,360||76.20|
|GUGGENHEIM CAPITAL LLC||10,883||10,949||0.61||35||46||31.43|
|Steward Partners Investment Advisory, Llc||45||45||0.00||0||0|
|Renaissance Technologies LLC||150,600||41,800||-72.24||489||174||-64.42|
|Private Advisor Group, LLC||15,000||63|
|Penobscot Investment Management Company, Inc.||0||27,000||0||113|
|Bank of New York Mellon Corp||36,880||154|
|STATE STREET CORP||23,629||99|
|BANK OF AMERICA CORP /DE/||1,000||6,695||569.50||3||28||833.33|
|PERCEPTIVE ADVISORS LLC||83,682||43,682||-47.80||272||182||-33.09|
|WELLS FARGO & COMPANY/MN||50||60||20.00||0||0|
|Wellington Shields Capital Management, LLC||725,348||790,256||8.95||2,357||3,295||39.80|
|Focused Wealth Management, Inc||45||45||0.00||0||0|
|UBS Group AG||10,872||5,373||-50.58||35||23||-34.29|
|Chicago Partners Investment Group LLC||27||27||0.00||0||0|
|BANK OF MONTREAL /CAN/||0||354||0||3|
|Alpine Partners VI, LLC||27,729||11,954||-56.89||90||50||-44.44|
|PRICE T ROWE ASSOCIATES INC /MD/||50,400||49,400||-1.98||164||206||25.61|
|Verition Fund Management LLC||15,835||66|
|Wellington Shields & Co., LLC||445,118||625,118||40.44||1,447||2,607||80.17|
|IHT Wealth Management, LLC||7,000||7,000||0.00||25||30||20.00|
|BlackRock Fund Advisors||35,958||37,886||5.36||40||44||10.00|
|MANUFACTURERS LIFE INSURANCE COMPANY, THE||2,871||2,726||-5.05||9||11||22.22|
|MILLENNIUM MANAGEMENT LLC||42,214||430,297||919.32||137||1,794||1,209.49|
|Raymond James Financial Services Advisors, Inc.||20,090||52,090||159.28||65||217||233.85|
|Laurion Capital Management LP||55,729||232|
|JP Morgan Chase & Co||9||9||0.00||0||0|
|LADENBURG THALMANN FINANCIAL SERVICES INC||45||2,046||4,446.67||0||8|
|BlackRock Investment Management, LLC||3,375||3,375||0.00||4||4||0.00|
|CITADEL ADVISORS LLC||20,097||84|
|CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM||136,518||136,518||0.00||444||569||28.15|
|GEODE CAPITAL MANAGEMENT, LLC||225,578||225,578||0.00||733||940||28.24|
|ROYAL BANK OF CANADA||17,649||17,545||-0.59||58||74||27.59|
|ELEMENT CAPITAL MANAGEMENT LLC||29,279||122|
|BlackRock Advisors LLC||7,740||7,740||0.00||9||9||0.00|
|Atlantic Trust Group, LLC||100||100||0.00||0||0|
|Jefferies Group LLC||27,000||113|
|EVERETT HARRIS & CO /CA/||10,002||10,002||0.00||33||42||27.27|
|NORTHERN TRUST CORP||73,987||73,987||0.00||240||308||28.33|
|BlueCrest Capital Management Ltd||26,709||111|
|GOLDMAN SACHS GROUP INC||18,861||178,063||844.08||61||743||1,118.03|
|CITADEL ADVISORS LLC||18,398||20,097||9.23||60||84||40.00|
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products (NASDAQ:CBPO), one of China's top five plasma-based biopharmas. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding. Headquartered in Beijing, CBPO operates plasma-gathering facilities and offers 20 plasma-based products. The offer, priced at $110 per share, represents a P/E ratio of 37 based on the past 12 months, but only 16. (76-1)
Good day, ladies and gentlemen, and welcome to Spectrum Pharmaceuticals First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, today’s conference is being recorded. (10-2)
James Watson, who co-discovered the double-helix structure of DNA in 1953, will lead a new international life science research center in the International Bio Valley, located in Shenzhen's Dapeng New Area. A groundbreaking ceremony was held last Friday with Dr. Watson in attendance. The new research center, which may be called the Watson Research Center of Life Science, will strive to find new, less expensive solutions to the problem of cancer and will be staffed by more than 1,000 scientists. (18-0)
GlaxoSmithKline commences late stage study with Benlysta (belimumab) and Roche's Rituxan (rituximab) in adult patients with systemic lupus erythematosus (SLE). (26-1)
as of ET